Investigators

Find a Member

Search by Name
Search by Keyword
Search by Program
Search by Theme
View Investigators by Last Name
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
Shivendra Singh, PhD
Program(s): Cancer Epidemiology and Prevention
Contact:
2.32A Hillman Cancer Research Pavilion
5117 Centre Ave
Pittsburgh PA
Phone: 412-623-3262
Research Interests and Keywords:
  • Cancer pharmacology
  • drug discovery
  • chemoprevention
  • dietary anti-cancer compounds
  • isothiocynates
  • organosulides
  • withaferin A
  • cancer prevention
Summary
The primary research interests of the Singh laboratory include molecular characterization of novel cancer chemopreventive agents and rational design of mechanism-driven combination chemoprevention regimens. Cellular and transgenic animal models are used to screen potential cancer chemopreventive constituents from dietary and medicinal plants. Cutting edge cellular, molecular biological, omics (metabolomics and proteomics), structural biology, and imaging techniques (MRI and bioluminescence) are used to (a) determine the mechanism of action of promising cancer chemopreventive agents, (b) monitor effects on cancer progression, and (c) identify biomarkers predictive of tissue exposure and possibly response. Some of the agents under active investigation in the Singh laboratory include: cruciferous vegetable-derived isothiocyanates, garlic-derived organosulides, and medicinal plant constituent withaferin A. As an example, recent published work from the Singh laboratory indicates suppression of glycolysis in mammary cancer prevention by withaferin A in a transgenic mouse model. Likewise, complementary cellular and molecular biological, targeted proteomics, and molecular modeling techniques were used to identify beta-tubulin as a novel target of cancer cell growth arrest by withaferin A (WA).
Top